ProKidney Corp. targets diabetic CKD with Rilparencel and expects Q2 2027 eGFR slope data for accelerated approval. Find out ...

Benitec Biopharma Inc. reports 100% responder rates for BB-301 with a mid-2026 FDA meeting ahead. See why BNTC stock is upgraded to buy.

The transaction materially strengthens Aclarion’s balance sheet, preserves capital structure integrity, and significantly extends the Company’s operating runway well past targeted near and medium-term ...

Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −Highlights Phase 2 data for ATH434 in Multiple System ...

FDA approvals, trial progress and early commercial momentum put several ASX healthcare companies in a strong position heading ...

Moderna (NasdaqGS:MRNA) is shifting away from self-funding new Phase III vaccine trials in response to increased vaccine hesitancy in the U.S. The company is seeking external partners to finance and ...

PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced the closing of a Series B extension, bringing the ...

Protect your Most Important Assets: Your Personal Information. GET your 14-Day FREE TRIAL following my link with AURA at NEW!

Former intelligence official Egisto Ott goes on trial in Vienna on Thursday, accused of spying for Russia in what is being ...

CalciMedica ( (CALC) ) has shared an announcement.

AtaiBeckley (ATAI) has drawn fresh attention after positive late stage BPL-003 data in treatment resistant depression, inclusion in the NASDAQ Biotechnology Index, a US$300 million capital raise, and ...